Condition: Relapsing Multiple SclerosisInterventions: Drug: Remibrutinib; Drug: TeriflunomideSponsor: Novartis PharmaceuticalsRecruiting Author:
Category: Clinical Trials
Information and news about current clinical trials
Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Condition: Multiple SclerosisInterventions: Drug: tolebrutinib 60mg; Drug: tolebrutinib 120mgSponsor: National Institute of Neurological Disorders and Stroke (NINDS)Recruiting Author:
Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
Condition: Multiple SclerosisIntervention: Drug: AnakinraSponsor: National Institute of Neurological Disorders and Stroke (NINDS)Recruiting Author:
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
Condition: Multiple Sclerosis (MS)Interventions: Drug: Ocrelizumab; Drug: rHuPH20Sponsor: Hoffmann-La RocheActive, not recruiting Author:
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
Condition: Multiple SclerosisInterventions: Drug: Teriflunomide; Drug: PlaceboSponsor: Genzyme, a Sanofi CompanyActive, not recruiting Author:
Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis
Condition: Multiple SclerosisInterventions: Drug: SAR441344 IV; Drug: placebo IV; Drug: SAR441344 SC; Drug: placebo SC; Drug: MRI contrast-enhancing preparationsSponsor: SanofiActive, not recruiting Author:
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-RemittingIntervention: Drug: OcrelizumabSponsor: Hoffmann-La RocheActive, not recruiting Author:
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple SclerosisInterventions: Drug: Interferon beta-1a; Drug: Ocrelizumab-matching placebo; Drug: Ocrelizumab; Drug: Interferon beta-1a-matching placeboSponsor: Hoffmann-La RocheActive, not recruiting Author:
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple SclerosisInterventions: Drug: Interferon beta-1a; Drug: Ocrelizumab-matching placebo; Drug: Ocrelizumab; Drug: Interferon beta-1a-matching placeboSponsor: Hoffmann-La RocheActive, not recruiting Author:
Multiple Sclerosis-Simvastatin Trial 2
Condition: Secondary Progressive Multiple Sclerosis (SPMS)Interventions: Drug: Simvastatin; Drug: PlaceboSponsors: University College, London; University of Edinburgh; Queen Mary University of London; London School of Hygiene and Tropical Medicine; University of Leeds; The Leeds Teaching Hospitals NHS Trust; Imperial College Healthcare NHS TrustActive, not recruiting Author:
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary ProgressiveInterventions: Drug: Ocrelizumab; Other: PlaceboSponsor: Hoffmann-La RocheActive, not recruiting Author:
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
Condition: Secondary Progressive Multiple SclerosisInterventions: Drug: BAF312; Drug: Baseline disease modifying therapies (DMTs)Sponsor: Novartis PharmaceuticalsActive, not recruiting Author: